Immune response developing in tumorous organism as a result of immunotherapy. Chance of recovery?
S-allylgutimine has immunostimulant and tumor cell inhibitory activities. This complex action may be a result of the stimulation of IL-2 production. The effectiveness of immunotherapy depends on the uncoupling of IL-2 downregulation. This principle can be widely used with those immunological diseases where IL-2 level is decreased through downregulation. The Kokonov reaction, which was used originally to indicate tumors, is presumably a marker of immunoreactivity. According to one hypothesis no specific antigen can be found on the surface of neoplastic cells but another type, 'weak antigen' appears, which originates from the alteration of a cell surface glycoprotein beta 1-6 saccharide chain branching that is directly related to the increased immune reactivity. The inhibition of downregulation enhances the elimination of neoplastic cells whose membrane surface glycoproteins are altered.
Vértesi
C
C
Pharmacological Laboratory of CHINOIN Pharmaceutical and Chemical Works Co. Ltd, Budapest, Hungary.
D000818:Animals; D002286:Carcinoma, Ehrlich Tumor / Q000276:immunology / Q000628:therapy; D006164:Guanylthiourea / Q000031:analogs & derivatives / Q000627:therapeutic use; D007167:Immunotherapy; D007376:Interleukin-2 / Q000096:biosynthesis; D008175:Lung Neoplasms / Q000276:immunology / Q000628:therapy; D051379:Mice; D008810:Mice, Inbred C57BL; D008954:Models, Biological; D009374:Neoplasms, Experimental / Q000276:immunology / Q000628:therapy*
D007376:Interleukin-2; C083344:S-allylgutimine; D006164:Guanylthiourea